SCHEMBL5425614

SCHEMBL5425614

Cc1c(NC(=O)CCCc2c[nH]c3ccccc23)c(=O)n(-c2ccccc2)n1-c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.57
KMT2A Q03164 7/20 0.55
KDM4E B2RXH2 2/20 0.54
ALDH1A1 P00352 2/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
HPGD P15428 2/20 0.54
MEN1 O00255 4/20 0.54
TDP1 Q9NUW8 1/20 0.53
CYP1A2 P05177 2/20 0.53
CYP2D6 P10635 2/20 0.53
CYP2C19 P33261 2/20 0.53
RECQL P46063 1/20 0.53
LMNA P02545 1/20 0.53
MAPK1 P28482 1/20 0.53
CYP3A4 P08684 1/20 0.50
CYP2C9 P11712 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
HCRTR1 O43613 1/20 0.48
MTNR1A P48039 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5428767 0.94 MAPT (0.53) MAPTKMT2AALDH1A1HPGDMEN1
SCHEMBL5814760 0.88 KLK6 (0.55) MAPTKMT2AKDM4EALDH1A1HPGD
SCHEMBL5429451 0.86 TSHR (0.61) MAPTKDM4EALDH1A1HPGDLMNA
SCHEMBL5431770 0.78 NPC1 (0.60) MAPTKMT2AKDM4EALDH1A1MEN1
SCHEMBL28373441 0.76 MAPT (0.60) MAPTKMT2AKDM4EALDH1A1L3MBTL1
SCHEMBL19399613 0.74 ALDH1A1 (0.74) MAPTKMT2AKDM4EALDH1A1L3MBTL1
SCHEMBL6643764 0.73 MEN1 (0.76) MAPTKMT2AKDM4EALDH1A1L3MBTL1
SCHEMBL14441237 0.72 MAPT (0.69) MAPTKMT2AKDM4EALDH1A1L3MBTL1
SCHEMBL3431608 0.72 MAPT (0.84) MAPTKMT2AKDM4EALDH1A1L3MBTL1
SCHEMBL29608427 0.71 MEN1 (0.68) MAPTKMT2AKDM4EALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070185115-A1 Novel ureido-and amido-pyrazolone derivatives ASTON UNIVERSITY (GB) 2007-08-09 US disclosed
US-20070185115-A1 Novel ureido-and amido-pyrazolone derivatives ASTON UNIVERSITY (GB) 2007-08-09 US disclosed
US-20070185115-A1 Novel ureido-and amido-pyrazolone derivatives ASTON UNIVERSITY (GB) 2007-08-09 US disclosed
EP-1628963-A1 NOVEL UREIDO - AND AMIDO-PYRAZOLONE DERIVATIVES Aston University (GB) 2006-03-01 EP disclosed
WO-2004106306-A1 NOVEL UREIDO - AND AMIDO-PYRAZOLONE DERIVATIVES ASTON UNIVERSITY (GB) 2004-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185115-A1 Novel ureido-and amido-pyrazolone derivatives CCKAR, CCKBR, GRPR MAPT 4870/4885KMT2A 4491/4885KDM4E 1996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.